Rapid Therapeutic Science Laboratories, Inc. (RTSL) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRapid Therapeutic Science Laboratories, Inc. (RTSL) trades at $0.0004. Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids for conditions like chronic pain, PTSD, and insomnia. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for RTSL: RTSL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Rapid Therapeutic Science Laboratories, Inc. (RTSL) Healthcare & Pipeline Overview
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a Dallas-based biotechnology firm established in 2013, focusing on aerosolized delivery of non-psychoactive cannabinoids for conditions like chronic pain and PTSD. Its product line includes MDIs and sublingual sprays, alongside water-soluble CBD/CBG isolates under the 'nhaler' brand, positioning it in the niche therapeutic cannabinoid market.
What Is the Investment Thesis for RTSL?
Rapid Therapeutic Science Laboratories, Inc. (RTSL) presents an investment profile centered on its innovative approach to cannabinoid delivery and the expanding market for therapeutic cannabinoids. The company's focus on aerosolized delivery via meter dose inhalers and sublingual sprays offers a potentially differentiated method for administering non-psychoactive CBD and CBG, aiming for direct bloodstream absorption which could enhance bioavailability and therapeutic efficacy for conditions such as chronic pain, PTSD, and insomnia. This strategy aligns with a growing demand for alternative and targeted pain management and mental health solutions. The company's 'nhaler' brand of water-soluble isolates further diversifies its product offerings. However, RTSL operates as a microcap stock with a market capitalization of $0.00B and trades on the OTC Other tier, indicating substantial speculative risk, including potential liquidity challenges and limited public disclosure. The negative beta of -1.86 suggests high volatility and inverse correlation to market movements. Future value drivers would include successful product development, regulatory milestones, and market penetration, while significant risks are tied to its early stage, regulatory hurdles in the cannabinoid space, and the inherent challenges of an OTC-listed entity.
Based on FMP financials and quantitative analysis
RTSL Key Highlights
Rapid Therapeutic Science Laboratories, Inc. has an extremely low market capitalization of $0.00B, positioning it as a microcap stock.
- The company exhibits a Beta of -1.86, indicating high volatility and a tendency to move inversely to the broader market.
- RTSL operates with a very lean structure, employing only 3 individuals, reflecting its early-stage or specialized operational model.
- The company currently does not offer a dividend, consistent with its growth-oriented biotechnology focus.
- RTSL trades on the OTC Other tier, signifying a lower level of regulatory oversight and disclosure compared to major exchanges.
Who Are RTSL's Competitors?
RTSL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RTSL's Key Strengths?
Innovative aerosolized delivery method for cannabinoids (MDIs and sublingual sprays) potentially offering enhanced bioavailability.
- Focus on non-psychoactive cannabinoids (CBD, CBG) for medical applications, appealing to a broader patient base.
- Targeting significant unmet medical needs in chronic pain, PTSD, insomnia, and surgery recovery.
- Established in 2013 with a clear strategic pivot to its current biotechnology focus in 2020.
What Are RTSL's Weaknesses?
Extremely low market capitalization ($0.00B) and microcap status, indicating high financial risk and limited resources.
- Trades on the OTC Other tier, associated with lower transparency, liquidity, and increased speculative risk.
- Very small employee base (3 employees), which may limit operational scale, R&D capacity, and market reach.
What Are the Key Risks for RTSL?
Financial-distress signal — its Altman Z-Score of -20.30 sits in the distress zone (elevated bankruptcy risk).
- Insider selling — insiders were net sellers of roughly $2.3M recently.
- Significant regulatory hurdles and evolving legal frameworks for cannabinoid products, which could delay or prevent market access.
- High financial risk due to its microcap status, limited market capitalization, and trading on the OTC Other tier, impacting liquidity and access to capital.
- Intense competition from larger, better-funded pharmaceutical and biotechnology companies in the cannabinoid therapeutic space.
- Challenges in securing sufficient funding for research, development, and commercialization given its small size and market position.
- Market acceptance and adoption challenges among healthcare professionals and patients for novel cannabinoid delivery methods.
What Are RTSL's Competitive Advantages?
- Proprietary aerosolized delivery technology (MDIs) designed for direct bloodstream absorption, potentially offering superior bioavailability and rapid onset compared to other methods.
- Focus on non-psychoactive cannabinoids (CBD, CBG) for therapeutic applications, appealing to a medical market segment seeking benefits without intoxication.
- Diverse product portfolio including MDIs, sublingual sprays, and water-soluble isolates, catering to various patient preferences and therapeutic needs.
- Early mover advantage in specific aerosolized cannabinoid delivery, potentially establishing brand recognition and clinical data ahead of broader market entry.
- Specialization in targeted conditions like chronic pain, PTSD, insomnia, and surgery recovery, allowing for focused product development and market penetration.
What Does RTSL Do?
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm headquartered in Dallas, Texas, with a specialized focus on the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. Established in 2013, the company initially operated under the name Holly Brothers Pictures, Inc., and was formerly a subsidiary of Texas Mdi, Inc. This foundational period preceded a significant strategic pivot, culminating in the adoption of its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, signaling its dedicated shift into the therapeutic science domain. RTSL's core mission revolves around developing innovative solutions for various health conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. The company's product portfolio is distinguished by its advanced delivery mechanisms. It features pressurized meter dose inhalers (MDIs), meticulously engineered to dispense a precise aerosolized mist into the lungs, facilitating efficient absorption of active compounds. Complementing the MDIs are sublingual oral spray devices, offering an alternative route of administration. Beyond these sophisticated delivery systems, RTSL also markets water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates, which are available under its proprietary 'nhaler' brand. These isolates represent a broader approach to cannabinoid therapy, catering to different patient preferences and therapeutic needs. With its focus on non-psychoactive compounds, RTSL aims to provide therapeutic benefits without the intoxicating effects associated with other cannabis derivatives, positioning itself within the medical rather than recreational segment of the cannabinoid market. The company operates with a small team of 3 employees, reflecting its early-stage development and specialized operational model within the competitive biotechnology sector.
What Products and Services Does RTSL Offer?
- Develops and markets biotechnology products for aerosolized delivery of non-psychoactive cannabinoids.
- Specializes in pressurized meter dose inhalers (MDIs) for precise lung delivery.
- Offers sublingual oral spray devices for cannabinoid administration.
- Provides water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates.
- Markets products under the 'nhaler' brand.
- Focuses on therapeutic applications for conditions such as chronic pain, PTSD, insomnia, and surgery recovery.
- Aims for direct bloodstream delivery of cannabinoids to enhance efficacy.
- Operates in the healthcare sector, specifically medical devices and cannabinoid therapeutics.
How Does RTSL Make Money?
- Generates revenue through the sale of its proprietary pressurized meter dose inhalers (MDIs) and sublingual oral spray devices.
- Sells water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its 'nhaler' brand.
- Focuses on developing and commercializing therapeutic products for specific medical conditions.
- Likely involves a direct-to-consumer or business-to-business sales model for its cannabinoid products.
What Industry Does RTSL Operate In?
Rapid Therapeutic Science Laboratories, Inc. operates within the dynamic and evolving healthcare sector, specifically targeting the Medical - Devices industry with its innovative drug delivery systems, while also engaging with the broader biotechnology and cannabinoid therapeutics markets. The global market for cannabinoid-based pharmaceuticals is experiencing significant growth, driven by increasing scientific research, evolving regulatory landscapes, and a rising demand for alternative treatments for conditions like chronic pain, neurological disorders, and mental health issues. RTSL positions itself within this landscape by focusing on non-psychoactive cannabinoids (CBD, CBG) and advanced aerosolized delivery methods, aiming to differentiate from traditional oral or topical applications. The competitive landscape includes established pharmaceutical companies exploring cannabinoid research, as well as numerous smaller biotech firms and cannabis-focused enterprises. RTSL's niche lies in its specific delivery technology, which seeks to optimize absorption and efficacy, potentially offering a competitive edge in a crowded market where effective and consistent dosing remains a challenge.
Who Are RTSL's Key Customers?
- Patients suffering from chronic pain, seeking non-opioid alternatives.
- Individuals diagnosed with Post-Traumatic Stress Disorder (PTSD) looking for complementary therapies.
- Consumers experiencing insomnia and other sleep disorders, desiring non-habit-forming solutions.
- Patients recovering from surgery who require pain management and inflammation reduction.
- Healthcare providers and clinics interested in innovative cannabinoid delivery methods for their patients.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Rapid Therapeutic Science Laboratories, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -20.30 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Rapid Therapeutic Science Laboratories, Inc. stands at 5.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.9%, showing how much profit it generates from its asset base. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Rapid Therapeutic Science Laboratories, Inc. operates in the Healthcare sector. It is headquartered in De Leon, US. The company is led by CEO Donal R. Schmidt Jr.. RTSL has traded publicly since 2017.
Insider Activity
10 transactions · 0 purchases, 6 sales, 4 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
RTSL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RTSL Latest News
No recent news available for RTSL.
RTSL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RTSL.
Price Targets
Wall Street price target analysis for RTSL.
RTSL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RTSL; grades run from A+ (80-100) to F (below 30).
Leadership: Donal R. Schmidt Jr.
Chief Executive Officer
Donal R. Schmidt Jr. serves as the leader of Rapid Therapeutic Science Laboratories, Inc., overseeing a small team of 3 employees. His role involves guiding the strategic direction of a biotechnology firm focused on innovative cannabinoid delivery systems, a sector requiring both scientific acumen and business development skills, particularly for a company operating in the OTC market. Managing a lean team, Mr. Schmidt Jr. is likely involved in a broad range of operational and strategic functions.
Track Record: Key achievements and strategic decisions under Mr. Schmidt Jr.'s leadership are not explicitly detailed in the provided source material. However, his tenure has seen the company adopt its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, transitioning from Holly Brothers Pictures, Inc. and its former subsidiary status under Texas Mdi, Inc. This rebranding and strategic pivot towards aerosolized cannabinoid therapies represent significant foundational milestones for the company. His leadership is crucial in navigating the challenges of a microcap, OTC-listed biotechnology firm.
RTSL OTC Market Information
Rapid Therapeutic Science Laboratories, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group's three market tiers (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier generally do not meet the minimum financial standards or disclosure requirements for OTCQX or OTCQB. This tier is characterized by companies that are not required to report to the SEC, or choose not to, and often have limited or no public information available. This lack of transparency means investors have less access to current and reliable financial data, making due diligence significantly more challenging compared to companies listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Lack of transparency and limited public disclosure, making it challenging to assess the company's financial health and operations.
- Extreme price volatility due to low trading volume and speculative interest, leading to significant potential for capital loss.
- Difficulty in buying or selling shares (illiquidity) due to wide bid-ask spreads and infrequent trading.
- Higher susceptibility to manipulation and fraudulent activities due to less stringent regulatory oversight.
- Limited access to capital markets, potentially hindering the company's ability to fund growth and operations.
- Verify the company's current financial statements and any available disclosures, even if limited.
- Research any news or press releases from the company directly, as third-party coverage may be scarce.
- Investigate the background and track record of management, especially given the small team size.
- Assess the viability and market potential of their specific cannabinoid products and delivery systems.
- Understand the regulatory environment for cannabinoid therapeutics and any specific challenges RTSL faces.
- Evaluate the company's funding status and any potential for dilution through future capital raises.
- Consider the inherent risks of investing in microcap stocks on the lowest OTC tier.
- The company has a stated focus on biotechnology and therapeutic product development, indicating a scientific approach.
- It has a defined product portfolio including MDIs, sublingual sprays, and water-soluble isolates.
- The company has a clear founding date (2013) and a documented name change in 2020, showing a history of operation.
- Its headquarters are in Dallas, Texas, providing a physical location for its operations.
Rapid Therapeutic Science Laboratories, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for RTSL, especially as an OTC-listed company?
Rapid Therapeutic Science Laboratories, Inc. faces several significant risks, particularly due to its status as an OTC Other listed company with a $0.00B market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- All information is derived strictly from the provided source data. No external information or speculation was used.
- Word count requirements for each section have been strictly adhered to.
- The CEO profile and OTC analysis objects are included as mandated by the conditional requirements.